<SEC-DOCUMENT>0001628280-25-051813.txt : 20251113
<SEC-HEADER>0001628280-25-051813.hdr.sgml : 20251113
<ACCEPTANCE-DATETIME>20251113060248
ACCESSION NUMBER:		0001628280-25-051813
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20251113
FILED AS OF DATE:		20251113
DATE AS OF CHANGE:		20251113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231
		LEGAL ENTITY IDENTIFIER:    	9695002Y8420ZB8HJE29

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		251475177

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		NON US STATE TERRITORY:  	FRANCE
		PROVINCE COUNTRY:   	I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a2511136k-iphxincorporated.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9dfbf4418f354d4c8a5444149a6b6e4e_1"></div><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:4.55pt"><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="margin-top:0.1pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-top:0.1pt;padding-left:199.2pt;padding-right:199.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12.5pt;font-weight:700;line-height:218%">Washington, D.C. 20549 FORM 6-K</font></div><div style="margin-top:0.5pt;padding-left:6.82pt;padding-right:6.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:240%">Date of report&#58; November 13, 2025</font></div><div style="padding-left:163.57pt;padding-right:163.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:240%">Commission File Number&#58; 001-39084</font></div><div style="margin-top:0.05pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma S.A.</font></div><div style="margin-top:0.45pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">(Translation of registrant's name into English)</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Innate Pharma S.A.</font></div><div style="margin-top:0.4pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">117 Avenue de Luminy&#8212;BP 30191</font></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">13009 Marseille, France</font></div><div style="margin-top:0.45pt;padding-left:4.52pt;padding-right:4.52pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">+ 33 (0) 4 30 30 30</font></div><div style="margin-top:0.45pt;padding-left:6.6pt;padding-right:6.6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">(Address of principal executive office)</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.55pt;padding-right:56.8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:240%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F &#91; X &#93;&#160;&#160;&#160;&#160;Form 40-F &#91; &#93;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INCORPORATION BY REFERENCE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K (excluding the quotation from Jonathan Dickinson, Chief Executive Officer at Innate Pharma) shall be deemed to be incorporated by reference into the registration statement on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1598599/000162828023042262/innatepharma-fx3.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form F-3</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (File No. 333-276164) and registration statement on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1598599/000159859924000067/innatepharma-formsx8final.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form S-8</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (File No. 333-282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.45pt;padding-left:6.57pt;padding-right:6.57pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%">EXHIBIT INDEX</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:5.55pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">Description</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:4.5pt"><font style="color:#0066cc;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%">99.1 &#160;&#160;&#160;&#160;</font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="a251113exhibit991.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">Press Release dated November 13, 2025</a></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9dfbf4418f354d4c8a5444149a6b6e4e_4"></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:5.55pt;padding-right:14.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:280.1pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:700;line-height:120%">INNATE PHARMA S.A.</font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:280.1pt;padding-right:5.8pt;text-indent:-274.6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:125%">Date&#58; November 13, 2025&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47; JONATHAN DICKINSON&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:125%"> Name&#58;&#160;&#160;&#160;&#160;Jonathan Dickinson</font></div><div style="padding-left:333.15pt;text-indent:-53.05pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8.5pt;font-weight:400;line-height:9.05pt">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div style="margin-top:0.45pt;padding-left:247.85pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a251113exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iee56be28428a40b797b20718f5568e3f_1"></div><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.4pt;padding-right:5.45pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">EXHIBIT 99.1</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">INNATE PHARMA REPORTS THIRD QUARTER 2025 BUSINESS UPDATE AND FINANCIAL RESULTS</font></div><div style="margin-top:0.45pt;text-align:center"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Marseille, France, November 13, 2025, 7&#58;00 A.M. CET</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14pt">Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in S&#233;zary syndrome</font></div><div style="margin-bottom:6pt;padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14pt">IPH4502 Nectin-4 ADC Phase 1 enrollment continues to progress well - pharmacologically active dose reached </font></div><div style="margin-bottom:6pt;padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14pt">Monalizumab PACIFIC-9 on track to deliver data in H2 2026</font></div><div style="margin-bottom:6pt;padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14pt">Cash position of &#8364; 56.4 million</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> as of September 30, 2025, anticipated cash runway until end Q3-2026</font></div><div style="margin-bottom:6pt;padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14pt">Conference call to be held today at 2&#58;00 p.m. CET &#47; 8&#58;00 a.m. ET</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Innate Pharma SA (Euronext Paris&#58; IPH&#59; Nasdaq&#58; IPHA) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Innate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) today announced its business update and financial results for the first nine months of 2025.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">This quarter highlights strong execution across our key programs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">,&#8221; said </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Jonathan Dickinson, Chief Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> of Innate Pharma. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">With FDA clearance to initiate TELLOMAK-3, we are advancing lacutamab toward its confirmatory Phase 3 and potential accelerated approval in S&#233;zary syndrome. We remain on track for dose-escalation data, from IPH4502, our Nectin-4 ADC, in the first half of 2026, followed by monalizumab PACIFIC-9 results in the second half of 2026. Together, these milestones position us well to deliver meaningful value for patients and shareholders as we continue to advance our differentiated portfolio</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:400;line-height:151%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:151%">Including short term investments (&#8364;6.1 million) and non-current financial instruments (&#8364;10.4 million).</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">*****</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Webcast and conference call will be held today at 2&#58;00pm CET (8&#58;00am ET)</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The live webcast will be available at the following link&#58; </font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;events.q4inc.com&#47;attendee&#47;424851735</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Analysts may also join via telephone, click here to register&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;events.q4inc.com&#47;analyst&#47;424851735&#63;pwd&#61;_b%5EEVw8x</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This information can also be found on the Investors section of the Innate Pharma website, </font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">*****</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Pipeline highlights&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Strategic focus</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">As previously announced, Innate Pharma is prioritizing its investment on what it believes are its highest-value clinical assets, IPH4502, lacutamab, and monalizumab (partnered with AstraZeneca)&#59; and advancing the next Antibody Drug Conjugates (ADCs) toward development, leveraging its pipeline of innovative targets. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Lacutamab (anti-KIR3DL2 antibody)&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cutaneous T Cell Lymphoma</font></div><div style="height:28.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Company announced on November 10 that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The planned confirmatory Phase 3 trial, TELLOMAK-3, is an open-label, randomized study designed to demonstrate the efficacy of lacutamab in patients with S&#233;zary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. The trial will include two independent cohorts&#58; one enrolling patients with S&#233;zary syndrome post-mogamulizumab treatment randomized 1&#58;1 to receive lacutamab or romidepsin, and one enrolling patients with Mycosis fungoides randomized 1&#58;1 to receive lacutamab or mogamulizumab. The primary endpoint of the study for both cohorts is progression-free survival (PFS) evaluated by blinded central review.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Data from the Phase 2 TELLOMAK trial in CTCL demonstrated durable activity, a favorable safety profile, and improvements in patients&#8217; quality of life. With this feedback from FDA, the Company is progressing towards the initiation of the confirmatory Phase 3 TELLOMAK-3 trial in H1 2026. FDA provided encouraging initial feedback on Innate Pharma&#8217;s proposed regulatory pathway, which could potentially include Accelerated Approval for S&#233;zary syndrome, once the Phase 3 trial is underway.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Company held a KOL event on October 28, 2025 on lacutamab and provided updates on the planned Phase 3 trial, the regulatory pathway in CTCL, and the commercial opportunity for lacutamab. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Peripheral T Cell lymphoma (PTCL)</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial, an investigator-sponsored, randomized controlled trial led by the Lymphoma Study Association (LYSA) to evaluate lacutamab in combination with chemotherapy GEMOX (gemcitabine and oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed&#47;refractory PTCL is ongoing and continues to recruit patients.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">IPH4502 (Nectin-4 exatecan ADC)&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Phase 1 trial will assess the safety, tolerability, and preliminary efficacy of IPH4502 in advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The first patient was dosed in the Phase 1 study in January 2025. Enrollment of the dose escalation part continues to progress well and is expected to be completed at the end of 2025 or in the first quarter of 2026. Pharmacologically active dose has been reached.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca&#58; </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The Phase 3 PACIFIC-9 trial run by AstraZeneca evaluating durvalumab (anti-PD&#8209;L1) in combination with monalizumab or AstraZeneca&#8217;s oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who have not progressed following definitive platinum-based concurrent chemoradiation therapy (CRT) is ongoing. Enrollment in the trial is complete, and data readouts are expected in H2 2026. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Other Clinical stage assets</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">IPH6501 (ANKET&#174; anti-CD20 with IL-2V, proprietary)&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> The Phase 1&#47;2 clinical trial is evaluating IPH6501 in B-cell Non-Hodgkin&#8217;s lymphoma (B-NHL). The study is planned to enroll up to 184 patients. Clinical sites are open in the US, Australia, and France. Enrollment in the dose escalation phase of the trial is complete. Clinical data are expected to be presented in 2026. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:28.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">IPH6101 (ANKET&#174; anti-CD123, proprietary)&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> Innate regained the rights to SAR&#8217;579&#47;IPH6101 in July 2025. Data from the Sanofi-led Phase 1&#47;2 study and Phase 2 preliminary dose expansion of the trial have been transferred to Innate and the Company is evaluating potential next steps.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">IPH5201 (anti-CD39 antibody, partnered with AstraZeneca)&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> The MATISSE Phase 2 clinical trial conducted by Innate in neoadjuvant lung cancer for IPH5201, an anti CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, is ongoing, and recruitment is on track.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">IPH5301 (anti-CD73, proprietary)&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> The investigator-sponsored CHANCES Phase 1 trial of IPH5301 with Institut Paoli-Calmettes is ongoing. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Corporate update</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">As previously announced, in line with its strategic focus, the Company intends to streamline its organization. Planned layoffs will be implemented through a redundancy plan, expected to be completed during the first half of 2026. A consultation with the Workers' Council is ongoing and the plan is subject to endorsement by the French authorities (Dreets). </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The ATM program, pursuant to which it may, from time to time, offer and sell to eligible investors a total gross amount of up to $75 million of American Depositary Shares (&#8220;ADS&#8221;) is still in place. As of September 30, 2025, no sales have been made under the program.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cash, cash equivalents and financial assets of the Company amounted to &#8364;56.4 million as of September 30, 2025. At the same date, financial liabilities amounted to &#8364;24.8 million. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Revenues for the first nine months of 2025 amounted to &#8364;2.3 million (&#8364;10.2 million for the same period in 2024). For the nine-month period, ended September 30, 2025, revenue from collaboration and licensing agreements mainly resulted from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca  and Sanofi.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">About Innate Pharma&#58;</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Innate Pharma is advancing a portfolio of differentiated potential first- and&#47;or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.  </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Information about Innate Pharma shares&#58;</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">ISIN code&#160;&#58; FR0010331421</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">Ticker code&#160;&#58; Euronext&#58; IPH Nasdaq&#58; IPHA</font></div><div style="height:28.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">LEI&#160;&#58; 9695002Y8420ZB8HJE29</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">Disclaimer on forward-looking information and risk factors&#58; </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, including the statements regarding the timing of dose-escalation data for IPH4502, the timing of results for monalizumab PACIFIC-9, the timing of lacutamab Phase 3 and potential acceleration thereof, the contours and planned enrollment of the upcoming trials and studies, and the planned streamlining of the organization, including layoffs. The use of certain words, including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s reliance on third parties to manufacture its product candidates, the Company&#8217;s commercialization efforts and the Company&#8217;s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (&#8220;Facteurs de Risque&#34;) section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http&#58;&#47;&#47;www.amf-france.org or on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company&#8217;s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:700;line-height:120%">For additional information, please contact&#58;</font></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Innate Pharma</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">St&#233;phanie Cornen</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">stephanie.cornen&#64;innate-pharma.fr </font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font><br></font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Investor Relations</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">investors&#64;innate-pharma.fr</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font><br></font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Medias</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">communication&#64;innate-pharma.fr </font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:28.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
